September 2026 • PharmaTimes Magazine • 4-5
6. TREATMENTS
7. COLLABORATIONS
8. CLINICAL TRIALS
9. CONDITIONS
10.Word of mouth
Oral semaglutide signals new phase for obesity treatment
16.Top table
Why communications strategy should never be an afterthought
20.Fortune favours the brave
Rediscovering an appetite for risk – fuelling biotech innovation
26.New build
NHS commissioning map redrawn – is your strategy keeping up?
34.Leap of fAIth
What does CIOMS XIV mean for AI use in pharmacovigilance?
14.Role with it
Clinicians have a vital part to play in guiding patients through obesity care
18.Time to heal
How better data sharing could save lives in the UK
25.Cell story
AI methods for regulator-ready real-world evidence in NSCLC
38.Go with the flow
From AI pilots to regulator-ready capabilities, the future is present
30.Risk assessment
Digital diagnostics are transforming liver care by enabling prevention
13.Connected trials
Addressing study complexity by meeting trial sites where they are.
22.Evolution
Future-ready pharma teams: building knowledge and capability
24.Future proof
Mad World Summit 2026 – the future of workplace well-being
28.UCB
Building the future of clinical research around the patients it serves
33.Joy of competing!
Who’s in, who’s winning and what’s next
36.New crew
Movin’ in out, movin’ on in